Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation

André Heeres, Hu Xu (First author), Denise MS van Marion (First author), Femke Hoogstra-Berends, Deli Zhang, Jean-Paul Seerden, Lizette Loen, Herman Steen, Robert H Henning, Bianca J J M Brundel

Onderzoeksoutput: ArticleAcademicpeer review

43 Downloads (Pure)

Samenvatting

Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA.

Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF.
Originele taal-2English
Pagina's (van-tot) 345—364
TijdschriftDrug design, development and therapy
Volume13
StatusPublished - 18 jan 2019

Keywords

  • hartaandoeningen

Vingerafdruk Duik in de onderzoeksthema's van 'Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation'. Samen vormen ze een unieke vingerafdruk.

  • Citeer dit

    Heeres, A., Xu , H., van Marion, D. MS., Hoogstra-Berends, F., Zhang, D., Seerden, J-P., Loen, L., Steen, H., Henning, R. H., & Brundel, B. J. J. M. (2019). Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. Drug design, development and therapy, 13, 345—364 .